Advanced search
2 files | 2.30 MB Add to list

Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3) : a double-blind, randomised, placebo-controlled phase 3 trial

(2019) LANCET. 393(10168). p.253-264
Author
Organization
Keywords
DIAGNOSED MULTIPLE-MYELOMA, HIGH-DOSE THERAPY, LENALIDOMIDE MAINTENANCE, IMPROVES SURVIVAL, BORTEZOMIB, DEXAMETHASONE, CHEMOTHERAPY, THALIDOMIDE, INDUCTION

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 844.09 KB
  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 1.46 MB

Citation

Please use this url to cite or link to this publication:

MLA
Dimopoulos, Meletios A. et al. “Oral Ixazomib Maintenance Following Autologous Stem Cell Transplantation (TOURMALINE-MM3) : a Double-blind, Randomised, Placebo-controlled Phase 3 Trial.” LANCET 393.10168 (2019): 253–264. Print.
APA
Dimopoulos, M. A., Gay, F., Schjesvold, F., Beksac, M., Hajek, R., Weisel, K. C., Goldschmidt, H., et al. (2019). Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3) : a double-blind, randomised, placebo-controlled phase 3 trial. LANCET, 393(10168), 253–264.
Chicago author-date
Dimopoulos, Meletios A., Francesca Gay, Fredrik Schjesvold, Meral Beksac, Roman Hajek, Katja Christina Weisel, Hartmut Goldschmidt, et al. 2019. “Oral Ixazomib Maintenance Following Autologous Stem Cell Transplantation (TOURMALINE-MM3) : a Double-blind, Randomised, Placebo-controlled Phase 3 Trial.” Lancet 393 (10168): 253–264.
Chicago author-date (all authors)
Dimopoulos, Meletios A., Francesca Gay, Fredrik Schjesvold, Meral Beksac, Roman Hajek, Katja Christina Weisel, Hartmut Goldschmidt, Vladimir Maisnar, Philippe Moreau, Chang Ki Min, Agnieszka Pluta, Wee-Joo Chng, Martin Kaiser, Sonja Zweegman, Maria-Victoria Mateos, Andrew Spencer, Shinsuke Iida, Gareth Morgan, Kaveri Suryanarayan, Zhaoyang Teng, Tomas Skacel, Antonio Palumbo, Ajeeta B. Dash, Neeraj Gupta, Richard Labotka, S. Vincent Rajkumar, on behalf of the TOURMALINE-MM3 study group, and Fritz Offner. 2019. “Oral Ixazomib Maintenance Following Autologous Stem Cell Transplantation (TOURMALINE-MM3) : a Double-blind, Randomised, Placebo-controlled Phase 3 Trial.” Lancet 393 (10168): 253–264.
Vancouver
1.
Dimopoulos MA, Gay F, Schjesvold F, Beksac M, Hajek R, Weisel KC, et al. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3) : a double-blind, randomised, placebo-controlled phase 3 trial. LANCET. 2019;393(10168):253–64.
IEEE
[1]
M. A. Dimopoulos et al., “Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3) : a double-blind, randomised, placebo-controlled phase 3 trial,” LANCET, vol. 393, no. 10168, pp. 253–264, 2019.
@article{8618779,
  author       = {Dimopoulos, Meletios A. and Gay, Francesca and Schjesvold, Fredrik and Beksac, Meral and Hajek, Roman and Weisel, Katja Christina and Goldschmidt, Hartmut and Maisnar, Vladimir and Moreau, Philippe and Min, Chang Ki and Pluta, Agnieszka and Chng, Wee-Joo and Kaiser, Martin and Zweegman, Sonja and Mateos, Maria-Victoria and Spencer, Andrew and Iida, Shinsuke and Morgan, Gareth and Suryanarayan, Kaveri and Teng, Zhaoyang and Skacel, Tomas and Palumbo, Antonio and Dash, Ajeeta B. and Gupta, Neeraj and Labotka, Richard and Rajkumar, S. Vincent and TOURMALINE-MM3 study group, on behalf of the and Offner, Fritz},
  issn         = {0140-6736},
  journal      = {LANCET},
  keywords     = {DIAGNOSED MULTIPLE-MYELOMA,HIGH-DOSE THERAPY,LENALIDOMIDE MAINTENANCE,IMPROVES SURVIVAL,BORTEZOMIB,DEXAMETHASONE,CHEMOTHERAPY,THALIDOMIDE,INDUCTION},
  language     = {eng},
  number       = {10168},
  pages        = {253--264},
  title        = {Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3) : a double-blind, randomised, placebo-controlled phase 3 trial},
  url          = {http://dx.doi.org/10.1016/S0140-6736(18)33003-4},
  volume       = {393},
  year         = {2019},
}

Altmetric
View in Altmetric
Web of Science
Times cited: